6.
Schreiber R, Old L, Smyth M
. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70.
DOI: 10.1126/science.1203486.
View
7.
Waldman A, Fritz J, Lenardo M
. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020; 20(11):651-668.
PMC: 7238960.
DOI: 10.1038/s41577-020-0306-5.
View
8.
Beatty G, Gladney W
. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2014; 21(4):687-92.
PMC: 4334715.
DOI: 10.1158/1078-0432.CCR-14-1860.
View
9.
Bol K, Schreibelt G, Gerritsen W, de Vries I, Figdor C
. Dendritic Cell-Based Immunotherapy: State of the Art and Beyond. Clin Cancer Res. 2016; 22(8):1897-906.
DOI: 10.1158/1078-0432.CCR-15-1399.
View
10.
Hiraoka N, Onozato K, Kosuge T, Hirohashi S
. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006; 12(18):5423-34.
DOI: 10.1158/1078-0432.CCR-06-0369.
View
11.
Beatty P, van der Geest R, Hashash J, Kimura T, Gutkin D, Brand R
. Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas. Cancer Immunol Immunother. 2016; 65(7):771-8.
PMC: 11028509.
DOI: 10.1007/s00262-016-1838-1.
View
12.
Gil Del Alcazar C, Huh S, Ekram M, Trinh A, Liu L, Beca F
. Immune Escape in Breast Cancer During to Invasive Carcinoma Transition. Cancer Discov. 2017; 7(10):1098-1115.
PMC: 5628128.
DOI: 10.1158/2159-8290.CD-17-0222.
View
13.
Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G
. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature. 2019; 571(7766):570-575.
DOI: 10.1038/s41586-019-1330-0.
View
14.
Chang M, Chen C, Lai M, Hsu H, Wu T, Kong M
. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997; 336(26):1855-9.
DOI: 10.1056/NEJM199706263362602.
View
15.
Chang M, You S, Chen C, Liu C, Lee C, Lin S
. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009; 101(19):1348-55.
DOI: 10.1093/jnci/djp288.
View
16.
Cheng L, Wang Y, Du J
. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel). 2020; 8(3).
PMC: 7565290.
DOI: 10.3390/vaccines8030391.
View
17.
de Sanjose S, Brotons M, Pavon M
. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2017; 47:2-13.
DOI: 10.1016/j.bpobgyn.2017.08.015.
View
18.
Ventura C, Luis A, Soares C, Venuti A, Paolini F, Pereira L
. The Effectiveness of Therapeutic Vaccines for the Treatment of Cervical Intraepithelial Neoplasia 3: A Systematic Review and Meta-Analysis. Vaccines (Basel). 2022; 10(9).
PMC: 9500864.
DOI: 10.3390/vaccines10091560.
View
19.
Page K, Melia M, Veenhuis R, Winter M, Rousseau K, Massaccesi G
. Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. N Engl J Med. 2021; 384(6):541-549.
PMC: 8367093.
DOI: 10.1056/NEJMoa2023345.
View
20.
Sokal E, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Leonard P, Moreels A
. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis. 2008; 196(12):1749-53.
DOI: 10.1086/523813.
View